Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has inaugurated its new Biopharma Capability Center in Hyderabad, reinforcing its commitment to India’s rapidly growing life sciences sector. The center marks a significant investment as part of Agilent’s strategic three-to-five-year growth roadmap for the region.
The state-of-the-art facility was officially inaugurated by Telangana’s Minister for Information Technology, Electronics, Communications, and Industries, Duddila Sridhar Babu, in the presence of Agilent’s global CEO, Padraig McDonnell.
Built to support the entire drug development life cycle, the center offers cutting-edge lab technologies, regulatory-ready workflows, and expert training. It is poised to become a hub of innovation, collaboration, and capability development, particularly in areas like biologics, biosimilars, and precision medicine.
The facility provides end-to-end analytical solutions spanning chromatography, mass spectrometry, cell analysis, and lab informatics. By replicating real-world lab environments, it enables companies to test quality and compliance, co-develop solutions, and accelerate product development for both domestic and global markets.
For startups, academic institutions, and R&D professionals in Hyderabad’s biopharma ecosystem, the center opens up access to world-class instrumentation, global expertise, and hands-on training aligned with international standards. It also aims to drive stronger industry-academia partnerships and foster local innovation.
“India is a strategic growth market for Agilent, and Hyderabad stands at the forefront of biopharma innovation,” said Padraig McDonnell, CEO of Agilent Technologies. “This new center reflects our commitment to innovation, collaboration, and customer-focused solutions.”
McDonnell also emphasized the company’s alignment with national priorities:
“This experience center reinforces our support for the ‘Make-in-India’ initiative—by enabling scalable, affordable, and sustainable solutions, nurturing local talent, and empowering innovation from within.”
Minister Sridhar Babu highlighted the center’s strategic importance:
“With its strong talent pool and focus on cutting-edge research, Hyderabad is shaping a future-ready healthcare ecosystem. Agilent’s new center strengthens Telangana’s leadership in life sciences and adds momentum to our innovation-driven growth.”
Telangana contributes nearly one-third of India’s pharmaceutical production and accounts for 40% of bulk drug exports. Hyderabad, in particular, has emerged as one of India’s most advanced life sciences hubs, with robust industry presence, research capabilities, and supportive policy frameworks.
The new center builds on Hyderabad’s legacy in generics and its increasing focus on advanced therapies and biologics. It brings in next-gen analytical tools and regulatory expertise to support both local product development and global regulatory compliance.
Earlier this year, Agilent launched its India Solution Center in Manesar, further deepening its presence in the country. With this expansion, Agilent is strengthening its partnerships with Indian biopharma companies and positioning India as a critical hub in its global innovation and customer engagement strategy.
“We’re already working closely with many of India’s leading biopharma innovators,” McDonnell added. “With this new capability center, we aim to co-create tailored solutions that address evolving needs across Indian and international markets.”